Shares of ProMis Neurosciences, developer of an amyloid-targeting treatment for Alzheimer’s disease, experienced a significant decline last week following an announcement from Acumen Pharmaceuticals. Acumen reported that its Alzheimer’s drug, which operates through a similar mechanism, did not succeed in slowing cognitive or functional decline in patients compared to a placebo during a mid-stage study. ProMis CEO Neil Warma expressed that the market’s reaction was an overreaction and not justified, suggesting that investors may be prematurely linking the failure of Acumen’s drug to the prospects of ProMis’ treatment.
This situation highlights the volatility in the biotech sector, particularly in the context of Alzheimer’s drug development. The market’s response could indicate a cautious sentiment among investors regarding similar therapies, which may affect funding and support for ongoing research in this area.
Source: statnews.com · Image: U.S. Department of Energy – Science – 362 037 001 (9571250756) by U.S. Department of Energy from United States, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
